Bladder Health Research Roundup: July 2026

Bladder medicine does not usually move fast. Most years bring small tweaks: a new dosing schedule here, a reformulated instillation there, and the fundamentals sit unchanged for a decade at a stretch. 2026 has been different.

This is the first edition of a monthly roundup pulling together the bladder health research actually worth your attention. The plan each month is simple. Pull the studies that matter, grade how solid they really are, and translate them into something you can use at your next appointment. No press-release hype. No overselling.

Six developments made the cut this month. One is a genuine first. One overturns advice that millions of people follow every day. And one is so early I almost left it out, except the signal was too interesting to ignore.

Key Takeaways

Gepotidacin (Blujepa) became the first new-class oral UTI antibiotic in over 20 years, approved after two phase 3 trials in roughly 3,000 women.
D-mannose failed its largest, most rigorous test: 598 women, no measurable benefit over placebo for preventing recurrent UTIs.
The MV140 sublingual UTI vaccine held up in long-term follow-up, with 54% of recipients still UTI-free at nine years.
A 2025 meta-analysis of 3.6 million patients tightened the link between anticholinergic overactive bladder drugs and dementia; the beta-3 agonists don’t carry the same signal.
TAR-200, a drug-releasing bladder device, cleared cancer in 82% of patients with a hard-to-treat tumour, though the trial had no comparison group.
Most of this bladder health research is early or single-arm. Only the D-mannose and gepotidacin results rest on large randomised trials.

A new-class UTI antibiotic, the first in over 20 years

Start with the one that genuinely surprised me.

For decades, treating a urinary tract infection meant reaching for the same handful of antibiotics, all variations on chemistry we have leaned on since the last century. Resistance has been quietly eating into how well they work. So a truly new class of antibiotic reaching approval is rarer than it sounds, and it is exactly what happened with gepotidacin.

Gepotidacin, branded Blujepa by GSK, is a first-in-class triazaacenaphthylene antibiotic. The mechanism is the interesting part: it jams two different bacterial enzymes that manage DNA at once, rather than the single target most older antibiotics hit, which is the kind of dual action that makes it harder for bacteria to develop resistance through a single mutation 1.

That is the theory. What about people?

GSK ran two phase 3 trials, EAGLE-2 and EAGLE-3, pitting gepotidacin against nitrofurantoin, a standard UTI workhorse, across roughly 3,000 women and adolescent girls 1. In EAGLE-2 the new drug matched nitrofurantoin (about 51% therapeutic success versus 47%). In EAGLE-3 it beat it outright: 58% versus 44%. On the strength of that data, the FDA approved it in March 2025 for women and girls 12 and older 2.

The catch is the gut. Diarrhoea showed up in about 16% of people taking it and nausea in roughly 9%, mostly mild, but that is not nothing when the alternative is a three-day course of something you tolerate fine. Gepotidacin is also strictly for uncomplicated infections, not kidney infections or complicated UTIs. And there is a quirk worth a passing mention: the same drug picked up a second FDA approval for gonorrhoea, which makes it a rare two-for-one in the antibiotic world.

For Australian readers, the practical answer is: not yet. Blujepa is not TGA-approved here, so nitrofurantoin and trimethoprim remain the go-to oral options while the rest of the world starts road-testing the new arrival. If your infections keep returning despite those drugs, the conversation to have now is about recurrent UTIs and prevention, not this specific antibiotic.

The UTI vaccine that keeps proving its staying power

Fifty-four percent still UTI-free, nine years after a single course. That is the number that keeps the MV140 vaccine in the conversation.

MV140, sold as Uromune, is a sublingual spray containing four inactivated bacteria that trains the immune system in the tissues where UTIs actually start. In its phase 3 trial, published in NEJM Evidence, most vaccinated women stayed infection-free through the efficacy window, against roughly a quarter of those on placebo 3. The new angle this year is durability: a long-term follow-up presented at the European Association of Urology found 54% of recipients were still UTI-free a mean of 4.5 years out.

Here is the honest limit. The controlled trial only tracked patients to twelve months, so everything past that point comes from observational follow-up rather than a randomised comparison. The long tail looks genuinely good, but it is weaker evidence than the headline year-one data.

Australia is actually ahead of the US here. MV140 is available through the TGA’s Special Access Scheme, while it remains unapproved in the States. We went deep on the nine-year numbers, the access pathways, and where the durability data gets shaky in our full MV140 breakdown.

D-mannose just failed its biggest test

This is the one to actually read if you spend money on supplements.

D-mannose, a simple sugar that is supposed to stop E. coli from sticking to the bladder wall, has ridden years of enthusiasm built on small studies, most of them run in specialist clinics. Then researchers ran the biggest, cleanest test yet. The MERIT trial enrolled 598 women with recurrent UTIs across 99 UK general practices, randomised them to daily D-mannose or a matching placebo, and blinded everyone involved 4.

It didn’t work. Over six months, 51.0% of the D-mannose group had another medically attended UTI, versus 55.7% on placebo. That gap is not statistically meaningful (the confidence interval comfortably crosses zero), and there was no difference in symptom severity or antibiotic use either. The authors’ conclusion was blunt: D-mannose should not be recommended to prevent UTIs in this setting 4.

There is a grain of nuance. MERIT tested prevention in ordinary primary-care patients, and it is possible narrower groups respond differently. But that is exactly the population buying D-mannose off the shelf, so for the most common use, the strongest evidence now points the other way.

You will still see D-mannose topping every “natural UTI cure” listicle. The largest trial says save your money. If prevention is your goal, the more defensible moves are the ones with better support, which we cover in 8 natural ways to prevent recurrent UTIs and in our head-to-head on cranberry versus D-mannose.

This month’s bladder research, ranked

Not every finding here carries the same weight. This is the whole month ranked by how much you should trust it, strongest evidence at the top.

Development	Area	Evidence tier	Headline number	What it means
D-mannose (MERIT)	UTI prevention	Large double-blind RCT	51% vs 55.7% (no benefit)	Strong evidence it doesn’t prevent UTIs
Gepotidacin (Blujepa)	UTI treatment	Two phase 3 RCTs + approval	58% vs 44% success	Genuinely new option, not yet in Australia
MV140 (Uromune)	UTI prevention	Phase 3 RCT + long-term follow-up	54% UTI-free at 9 years	Promising, but long-term data is observational
TAR-200 (Inlexzo)	Bladder cancer	Single-arm phase 2b + approval	82% complete response	Big effect, but no control group
Anticholinergics & dementia	Overactive bladder	Meta-analysis of observational data	3.6M patients pooled	A real association, not proof of cause
Sunobinop	Interstitial cystitis	Phase 1b	41% vs 9% improved	Early signal, needs a proper trial

The overactive bladder drug that keeps getting tied to dementia

Pool eight studies and 3.6 million patients together, and the signal does not wash out.

A 2025 systematic review and meta-analysis looked at anticholinergic drugs used for overactive bladder, the family that includes oxybutynin, solifenacin, and tolterodine. Compared with people who took no drug and with people on newer beta-3 agonists, anticholinergic users had a higher rate of incident dementia 5. The individual studies have put the increase in the region of 20 to 30% for the most-implicated drugs, and it climbs with cumulative dose and duration.

The word to hold onto is association. This is observational data, so it cannot prove the drugs cause dementia; sicker patients and shared risk factors always muddy the picture. But the finding has now been reproduced enough times, in enough countries, that most urologists treat it as a real consideration rather than a statistical fluke.

The practical upside is that there is a clear alternative. Mirabegron and vibegron, the beta-3 agonists, relax the bladder through a different pathway and do not carry the same dementia signal. If you are over 65 and have been on an anticholinergic for years, that is a switch worth raising. We break down the numbers, the drug-by-drug differences, and how to have that conversation in our piece on overactive bladder medication and dementia risk.

An 82% response rate in hard-to-treat bladder cancer

Eighty-two percent of patients had no detectable cancer left. For the tumour in question, that is a genuinely big number.

TAR-200, now branded Inlexzo, is a small silicone device that a urologist places inside the bladder, where it slowly releases the chemotherapy drug gemcitabine over weeks. It is built for a brutal problem: bladder cancer that keeps growing after BCG immunotherapy has failed, specifically the non-muscle-invasive form with carcinoma in situ. Until recently, the main option for many of these patients was removing the bladder entirely.

In the SunRISe-1 trial, 83 patients received TAR-200 on its own. A confirmed complete response, meaning no cancer detectable on biopsy and cytology, showed up in 82%, and just over half were still in remission a year later 6. The FDA approved it in September 2025 7. It is done in an outpatient clinic, no general anaesthetic required.

The honest asterisk: this was a single-arm study with no comparison group, so the response rate cannot be read as a head-to-head win over anything. It is also US-only for now. Still, for people staring down bladder removal, a bladder-sparing option this effective is the kind of result that changes the conversation.

Interstitial cystitis gets an early signal worth watching

Now the one I almost cut.

Interstitial cystitis, the chronic bladder pain condition, has one of the emptiest medicine cabinets in urology. Almost nothing works reliably, and new drug candidates fail routinely. So when a first-in-class compound called sunobinop posted a positive early trial, it earned a place here despite how preliminary it is.

In a phase 1b study, 41% of patients on sunobinop reported marked or moderate improvement in their symptoms, against 9% on placebo, including less pain and less urinary urgency. That is a wide gap. It is also a phase 1b trial. A few dozen patients, early-stage, exactly the kind of result that evaporates as often as it holds up when a larger trial follows. Read it as a reason for cautious hope, not a treatment you can ask for.

What this means for you

Strip away the trial names and this month tells one story: a widening gap between what the research shows and what you can actually get, especially in Australia. Here is how it lands for real decisions.

If you take D-mannose to prevent UTIs. The best evidence no longer backs it. It is harmless, so there is no rush, but your prevention budget is better spent on strategies with stronger support, or on a proper plan with your GP.

If you are older and on an anticholinergic. Do not stop on your own. Do book a review to ask whether a beta-3 agonist like mirabegron fits your situation, particularly if you have been on oxybutynin for years.

If your UTIs keep coming back. MV140 is reachable in Australia through the Special Access Scheme today, and newer antibiotics like gepotidacin are widening the toolkit elsewhere. Both are worth raising with a doctor who treats a lot of recurrent infection.

None of this changes the basics. Fever, flank pain, or blood in your urine means see a doctor now, not next month. New research shifts the odds on prevention and long-term management; it does not treat an infection that is already underway.

What readers are asking this month

Should I stop taking D-mannose after the 2024 trial?

The MERIT trial found no measurable benefit over placebo for preventing recurrent UTIs in 598 women. D-mannose is safe, so there is no urgency to stop, but if you are buying it daily purely to prevent infections, the best evidence no longer supports that use. It is worth discussing proven alternatives with your GP.

Is the new UTI antibiotic gepotidacin available in Australia?

Not yet. Gepotidacin, sold as Blujepa, was approved by the US FDA in March 2025 but has not been approved by the TGA in Australia. Australian doctors still reach for nitrofurantoin and trimethoprim as first-line oral options for uncomplicated UTIs.

Which overactive bladder medications are linked to dementia?

The anticholinergic drugs, including oxybutynin, solifenacin, and tolterodine, are the ones tied to higher dementia risk in large studies. The beta-3 agonists mirabegron and vibegron do not show the same signal. The risk climbs with higher doses, longer use, and older age, so do not stop abruptly. Ask your doctor about switching.

Is D-mannose or cranberry better for preventing UTIs now?

Both have mixed evidence. Standardised cranberry with measured proanthocyanidins has a modest signal in Cochrane reviews for some women, while D-mannose has just failed its largest, most rigorous trial. Neither replaces medical care if you get frequent infections.

What is TAR-200 and who is it for?

TAR-200, sold as Inlexzo, is a small device placed inside the bladder that slowly releases the chemotherapy drug gemcitabine. The US FDA approved it in September 2025 for BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ. In its trial, 82% of patients had a complete response, and it lets some people avoid bladder removal.

What is the most important bladder health research of 2026 so far?

For everyday decisions, the D-mannose null result and the approval of gepotidacin will change the most, because they touch millions of people managing UTIs. The MV140 vaccine and TAR-200 cancer data matter enormously for the specific groups they affect, even though those groups are smaller.

What’s next in bladder health research

The through-line this month was access: strong data that has not yet reached Australian shelves, and popular remedies that the data no longer supports. Next month we will track where the gepotidacin rollout lands, any TGA movement on the newer options, and fresh results in overactive bladder and interstitial cystitis. If you follow bladder health research for one reason, make it this: the gap between a promising headline and a proven, available treatment is usually where the real story lives.

References

Wagenlehner F, et al. Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3 trials. The Lancet. 2024;403(10428):741-755. ScienceDirect
GSK. Blujepa (gepotidacin) approved by US FDA for treatment of uncomplicated urinary tract infections (uUTIs) in female adults and pediatric patients 12 years of age and older. 2025. GSK
Sublingual MV140 for prevention of recurrent urinary tract infections. NEJM Evidence. 2022. NEJM Evidence
Hayward G, et al. d-Mannose for prevention of recurrent urinary tract infection among women: a randomized clinical trial (MERIT). JAMA Internal Medicine. 2024;184(6):619-628. PMC
Risk of dementia in patients treated with anticholinergics for overactive bladder syndrome: a systematic review and meta-analysis. Neurological Sciences. 2025. PubMed
TAR-200 for Bacillus Calmette-Guérin-unresponsive high-risk non-muscle-invasive bladder cancer: results from the phase IIb SunRISe-1 study. Journal of Clinical Oncology. 2025. JCO
Urology Times. FDA approves gemcitabine intravesical system for BCG-unresponsive high-risk NMIBC. 2025. Urology Times
Purdue Pharma. Results from sunobinop phase 1b study in patients with interstitial cystitis/bladder pain syndrome announced. 2025. Purdue Pharma